For example, the identification of the PIK3CA gene mutation makes it possible to identify a special group of patients (PIK3CA-positive breast cancer) who receive the greatest benefit from molecular-targeted anti-PI3K therapy [90,91,92]. The gene discussed is PIK3CA; the disease is breast carcinoma.